Chromatin Regulation / Acetylation
- Chromatin Regulation / Acetylation
PhosphoSitePlus®：
H3
- 推奨プロトコール
推奨アプリケーションで優れたパフォーマンスを発揮するXP®モノクローナル抗体をお試しください : 4473
Pan-Methyl Histone H3 (Lys9) Antibody |
イイネ！(0) | 
|
| CSTコード | 包装 | 希望納入価格 (円) |
国内在庫  2012年2月8日17時20分 現在 |
|
|---|---|---|---|---|
| #4069S | 100 μL | 57,000 | ログインすると国内在庫状況がご確認いただけます。
|
Histone H3 XP®モノクローナル抗体 | Histone H3抗体製品一覧
|
4069 の推奨プロトコール 最適な結果を得るために：Cell Signaling Technology (CST) 社は、各製品の推奨プロトコールを使用することを強くお薦めいたします。 注：各製品に最適化されたプロトコールをリンクしています。 |
|---|
| 用途（希釈倍率） | |
|---|---|
| ウェスタンブロッティング（1:1,000）、免疫沈降（1:25）、免疫蛍光細胞染色（IF-IC）（1:500）、ChIP（1:25） |
| 種交差性 | |
|---|---|
| ヒト、マウス、ラット、サル、ゼブラフィッシュ |
| 特異性・感度 | |
|---|---|
| 内在性レベルのLys9がメチル化（モノメチル化、ジメチル化、トリメチル化）されたHistone H3タンパク質を検出します。Lys27がメチル化（モノメチル化、ジメチル化、トリメチル化）されたHistone H3タンパク質とは交差しません。 |
| 検出タンパク質の分子量 | |
|---|---|
| 17 kDa |
| 使用抗原 | |
|---|---|
| Lys9がジメチル化されたHistone H3 タンパク質N末端近傍領域（合成ペプチド） |
| 抗体の由来 | |
|---|---|
| ウサギ |
| 貯法 | |
|---|---|
| -20℃ |
| 社内データ |
|---|
推奨アプリケーションで優れたパフォーマンスを発揮するXP®モノクローナル抗体をお試しください : 4473
Western Blotting
Western blot analysis of whole cell lysates from HeLa, NIH/3T3, C6 and COS cells, using Pan-Methyl-Histone H3 (Lys9) Antibody.
IF-IC
DAPI staining (left) and immunofluorescent analysis (right) of NIH/3T3 cells, using Pan-Methyl-Histone H3 (Lys9) Antibody.
Chromatin IP
Chromatin immunoprecipitations were performed with cross-linked chromatin from 4 x 106 HeLa cells and either 20 μl of Pan-Methyl-Histone H3 (Lys9) Antibody or 2 μl of Normal Rabbit IgG #2729, using SimpleChIP® Enzymatic Chromatin IP Kit (Magnetic Beads) #9003. The enriched DNA was quantified by real-time PCR using SimpleChIP® Human AFM Intron 1 Primers #5098, SimpleChIP® Human α Satellite Repeat Primers #4486, SimpleChIP® Human RPL30 Exon 3 Primers #7014, and SimpleChIP® Human GAPDH Exon 1 Primers #5516. The amount of immunoprecipitated DNA in each sample is represented as signal relative to the total amount of input chromatin, which is equivalent to one.
ELISA-Peptide
Pan-Methyl-Histone H3 (Lys9) Antibody specificity was determined by peptide ELISA. The graph depicts the binding of the antibody to pre-coated di-methyl histone H3 (Lys9) peptide in the presence of increasing concentrations of various competitor peptides. As shown, only the mono-, di- and tri-methyl histone H3 (Lys9) peptides competed away binding of the antibody.
| バックグラウンド |
|---|
The nucleosome, made up of four core histone proteins (H2A, H2B, H3, and H4), is the primary building block of chromatin. Originally thought to function as a static scaffold for DNA packaging, histones have now been shown to be dynamic proteins, undergoing multiple types of post-translational modifications, including acetylation, phosphorylation, methylation, and ubiquitination (1). Histone methylation is a major determinant for the formation of active and inactive regions of the genome and is crucial for the proper programming of the genome during development (2,3). Arginine methylation of histones H3 (Arg2, 17, 26) and H4 (Arg3) promotes transcriptional activation and is mediated by a family of protein arginine methyltransferases (PRMTs), including the co-activators PRMT1 and CARM1 (PRMT4) (4). In contrast, a more diverse set of histone lysine methyltransferases has been identified, all but one of which contain a conserved catalytic SET domain originally identified in the Drosophila Su(var)3-9, Enhancer of zeste, and Trithorax proteins. Lysine methylation occurs primarily on histones H3 (Lys4, 9, 27, 36, 79) and H4 (Lys20) and has been implicated in both transcriptional activation and silencing (4). Methylation of these lysine residues coordinates the recruitment of chromatin modifying enzymes containing methyl-lysine binding modules such as chromodomains (HP1, PRC1), PHD fingers (BPTF, ING2), tudor domains (53BP1), and WD-40 domains (WDR5) (5-8). The discovery of histone demethylases such as PADI4, LSD1, JMJD1, JMJD2, and JHDM1 has shown that methylation is a reversible epigenetic marker (9).
- Peterson, C.L. and Laniel, M.A. (2004) Curr. Biol. 14, R546-R551.
- Kubicek, S. et al. (2006) Ernst Schering Res. Found Workshop, 1-27.
- Lin, W. and Dent, S.Y. (2006) Curr. Opin. Genet. Dev. 16, 137-142.
- Lee, D.Y. et al. (2005) Endocr. Rev. 26, 147-170.
- Daniel, J.A. et al. (2005) Cell Cycle 4, 919-926.
- Shi, X. et al. (2006) Nature 442, 96-99.
- Wysocka, J. et al. (2006) Nature 442, 86-90.
- Wysocka, J. et al. (2005) Cell 121, 859-872.
- Trojer, P. and Reinberg, D. (2006) Cell 125, 213-217.
| 使用例 | |
|---|---|
| 製品をご使用いただいて研究を発表されましたら、ぜひお知らせください。 |
本製品は試験研究用です。